Cellectis (CLLS) EPS (Weighted Average and Diluted) (2015 - 2025)
Cellectis (CLLS) recorded quarterly EPS (Weighted Average and Diluted) of -$438633.3 in Q4 2025, down 844.71% quarter-over-quarter from $58900.0 in Q3 2025, and down 670810944.88% on a YoY basis from N/an in Q4 2024.
Cellectis (CLLS) EPS (Weighted Average and Diluted) (2015 - 2025) Analysis & Trends
Cellectis' EPS (Weighted Average and Diluted) history runs 8 years deep, the most recent figure standing at -$438633.3 for Q4 2025.
- In Q4 2025, EPS (Weighted Average and Diluted) fell 670810944.88% year-over-year to -$438633.3; the TTM figure through Dec 2025 stood at -$438633.3 (down 670810944.88% YoY), while the FY2025 annual figure was -$0.67, down 63.41% from the prior year.
- EPS (Weighted Average and Diluted) was -$438633.3 for Q4 2025 at Cellectis, down from $58900.0 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $58900.0 in Q3 2025 to a low of -$438633.3 in Q4 2025.
- Historically, EPS (Weighted Average and Diluted) has averaged -$56061.8 across 5 years, with a median of -$0.63 in 2022.
- The sharpest annual moves came in 2024 and 2025: EPS (Weighted Average and Diluted) soared 109.62% in 2024, then tumbled 670810944.88% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.56 in 2021, then slipped by 5.56% to -$0.59 in 2022, then decreased by 15.5% to -$0.68 in 2023, then jumped by 109.62% to $0.07 in 2024, then plunged by 670810944.88% to -$438633.3 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at -$438633.3 (Q4 2025), $58900.0 (Q3 2025), and -$56514.3 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -438,633.33 |
| Sep 30, 2025 | 58,900.00 |
| Jun 30, 2025 | -56,514.29 |
| Dec 31, 2024 | 0.07 |
| Jun 30, 2024 | -90,250.00 |
| Dec 31, 2023 | -0.68 |
| Jun 30, 2023 | -0.20 |
| Dec 31, 2022 | -0.59 |
| Dec 31, 2021 | -0.56 |
| Jun 30, 2021 | -34,118.80 |
| Jun 30, 2020 | -42,451.32 |
| Jun 30, 2019 | -29,084.35 |
| Mar 31, 2015 | 26,721.74 |